drugset / Trial / NCT00299507
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to evaluate the effect of the dose concentration and administration frequency of Anecortave Acetate (AA) on visual acuity (VA) and lesion size when administered by posterior juxtascleral depot (PJD) every 3 months (AA 15 mg) or 6 months (AA 15 mg, AA 30 mg) in patients with exudative age-related macular degeneration (AMD).
Timeline
- Start
- 2005-03
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anecortave Acetate | Small molecule | 15 mg | Other |
| Subject | Anecortave Acetate | Small molecule | 30 mg | Other |